RENATA Stock Overview
Renata Limited manufactures, markets, distributes, and exports human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Renata PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ৳699.50 |
52 Week High | ৳1,217.90 |
52 Week Low | ৳695.50 |
Beta | 0.032 |
1 Month Change | -12.61% |
3 Month Change | -28.41% |
1 Year Change | -42.57% |
3 Year Change | -36.47% |
5 Year Change | -14.85% |
Change since IPO | 23,902.84% |
Recent News & Updates
Recent updates
Shareholder Returns
RENATA | BD Pharmaceuticals | BD Market | |
---|---|---|---|
7D | -6.9% | -3.6% | -2.6% |
1Y | -42.6% | -17.6% | -19.8% |
Return vs Industry: RENATA underperformed the BD Pharmaceuticals industry which returned -17.6% over the past year.
Return vs Market: RENATA underperformed the BD Market which returned -19.8% over the past year.
Price Volatility
RENATA volatility | |
---|---|
RENATA Average Weekly Movement | 3.1% |
Pharmaceuticals Industry Average Movement | 6.4% |
Market Average Movement | 5.2% |
10% most volatile stocks in BD Market | 7.8% |
10% least volatile stocks in BD Market | 3.1% |
Stable Share Price: RENATA's share price has been volatile over the past 3 months.
Volatility Over Time: RENATA's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1972 | 7,119 | Syed S. Kabir | www.renata-ltd.com |
Renata Limited manufactures, markets, distributes, and exports human pharmaceuticals, animal health medicines, nutritionals, and vaccines in Bangladesh. Its pharmaceutical products include antimicrobials, anti-hypertensive, anti-angina, anti-diabetic, eye-ear and topical preparation, antigout, NSAID, anti-spasmodic, steroid, anti-osteoporotic, anti-allergic, cardiovascular, CNS, hormone, anti-cancer, oxytocic, anti-fibrinolytic, anti-asthma, expectorant, oral rehydration saline, narcotic analgesic, antipyretic/analgesic, antiemetic, anesthetic, antiviral, and other products. The company also offers lipid lowering, antiulcer, anti-parasitic and anti-protozoal, anti-fungal, anti-tuberculosis, and gastroprokinetic agents; and vitamins and minerals, and amino acid supplements.
Renata PLC Fundamentals Summary
RENATA fundamental statistics | |
---|---|
Market cap | ৳80.23b |
Earnings (TTM) | ৳2.29b |
Revenue (TTM) | ৳36.47b |
35.0x
P/E Ratio2.2x
P/S RatioIs RENATA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RENATA income statement (TTM) | |
---|---|
Revenue | ৳36.47b |
Cost of Revenue | ৳22.25b |
Gross Profit | ৳14.22b |
Other Expenses | ৳11.92b |
Earnings | ৳2.29b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 20.00 |
Gross Margin | 38.99% |
Net Profit Margin | 6.29% |
Debt/Equity Ratio | 52.2% |
How did RENATA perform over the long term?
See historical performance and comparison